Medical Oncologist
Eligibility for Lenvatinib
Who Is Eligible for — Lenvatinib?
Lenvatinib is approved for four cancer types, but within each of those, not everyone qualifies. Your eligibility depends on your specific diagnosis, how far the disease has progressed, which treatments you have already had, and in one cancer type, a biomarker test result from your tumour tissue.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Four cancer types — Lenvatinib is approved for thyroid, liver, kidney, and endometrial cancer — but the eligibility criteria within each are specific.
- Biomarker testing matters — For endometrial cancer, a tissue test result for MMR or MSI determines how lenvatinib is given. For thyroid cancer, your history with radioiodine is the key criterion.
- Stage and fitness are assessed — Your overall health and performance status are weighed alongside cancer type, because lenvatinib has a significant side effect profile that your team needs to be confident you can manage.
- Eligibility is a clinical decision — Your oncologist decides based on test results and clinical judgement, not the cancer label alone. Ask for those results in writing.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Lenvatinib is approved in India for four cancer types: differentiated thyroid cancer that no longer responds to radioiodine, unresectable liver cancer, advanced kidney cancer, and advanced endometrial cancer. Whether you qualify depends on your cancer type, stage, prior treatment, and in some cases a biomarker test on your tumour tissue.
What does your oncologist look at to decide if lenvatinib suits you?
Lenvatinib blocks signals that tumours use to build new blood vessels. It has specific approved uses — eligibility is not just about the cancer label but about the stage, your prior treatment history, and how well key organs are functioning.
Your general fitness, measured by a performance status score, is also part of the assessment. Lenvatinib has a demanding side effect profile, and your oncologist needs to be confident the likely benefit is worth that profile for you specifically.
For endometrial cancer, a laboratory test on your tumour tissue — checking for mismatch repair proteins (MMR) or microsatellite instability (MSI) — is required before treatment begins. This result determines how lenvatinib is combined with other medicines.
Signs you may be a candidate for lenvatinib
- Your cancer is differentiated thyroid cancer that has stopped responding to radioiodine treatment
- Your cancer is unresectable hepatocellular carcinoma (liver cancer) with well-preserved liver function
- Your cancer is advanced or metastatic renal cell carcinoma (kidney cancer)
- Your cancer is advanced endometrial cancer that has progressed after platinum-based chemotherapy
- Your performance status is rated 0 or 1 — you are fully active or have only minor limitations
- Your blood tests show adequate kidney function, liver function, and blood cell counts
- Your blood pressure is controlled, or can be controlled before starting treatment
- You are not pregnant and are using reliable contraception if of childbearing potential
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which cancers is lenvatinib approved for, and what must be true?
| Cancer type | Key eligibility requirement | Biomarker or classification test | How lenvatinib is given |
|---|---|---|---|
| Differentiated thyroid cancer | Cancer is radioiodine-refractory — it has stopped responding to radioactive iodine | No molecular biomarker required; RAI-refractory status confirmed clinically | Alone (monotherapy) |
| Hepatocellular carcinoma (liver) | Disease is unresectable; liver function is adequately preserved | No biomarker required; Child-Pugh classification is assessed | Alone (monotherapy) |
| Renal cell carcinoma (kidney) | Advanced or metastatic disease | Clear cell histology confirmed on tumour pathology | With pembrolizumab or everolimus, depending on regimen |
| Endometrial carcinoma (uterus) | Advanced disease that has progressed after platinum-based chemotherapy | MMR or MSI test on tumour tissue is required before starting | With pembrolizumab |
Questions about your eligibility
I have thyroid cancer but was never given radioiodine. Am I eligible?
Lenvatinib is approved specifically for differentiated thyroid cancer that is radioiodine-refractory — meaning radioiodine was tried and the cancer either did not respond or has stopped responding over time. If radioiodine has not been tried, your oncologist would first assess whether it is appropriate for your situation. In some cases, radioiodine is unsuitable from the start — due to the cancer subtype or how spread it is — and your oncologist may document RAI-refractory status on that clinical basis. Ask your team how your situation is classified before assuming you are or are not eligible.
My liver cancer is rated Child-Pugh B. Does that exclude me?
The evidence base for lenvatinib in liver cancer was built primarily in patients with Child-Pugh A liver function, meaning the liver is relatively well-preserved. Child-Pugh B indicates more significant liver impairment. Current ESMO and NCCN guidance does not support lenvatinib routinely in that setting because the risk of harm increases when liver function is already compromised. If you are Child-Pugh B, ask your oncologist what the appropriate alternative is for your stage and overall condition. Being in this group does not mean there are no options — it means a different treatment fits your liver status better.
What is the MMR or MSI test, and why does it matter for endometrial cancer?
MMR stands for mismatch repair — proteins in your cells that correct errors when DNA is copied. MSI stands for microsatellite instability, a pattern that appears when those proteins are not working. In endometrial cancer, NCCN and ESMO guidance requires this test result before treatment decisions are made. Lenvatinib combined with pembrolizumab is recommended for tumours that test proficient-MMR (pMMR) or microsatellite-stable (MSS), meaning the repair proteins are present and working. If your tumour shows deficient MMR or high MSI, your oncologist may recommend a different approach, as the evidence base points a different way.
My performance status is 2. Does that rule me out?
Most clinical trials that established lenvatinib's evidence enrolled patients with a performance status of 0 or 1. A status of 2 does not automatically exclude you, but it does mean your oncologist will weigh the expected benefit against the side effect burden more carefully. Lenvatinib commonly causes blood pressure changes, fatigue, appetite loss, and gut symptoms — effects that can be harder to manage if you are already significantly limited in daily activity. Your oncologist makes this judgement based on your full health picture, not the number alone. Ask them to explain how your fitness score affects their recommendation.
Can lenvatinib be used before other treatments, or only after they have failed?
It depends on your cancer type. In differentiated thyroid cancer and in hepatocellular carcinoma, lenvatinib is approved as a first-line treatment — no prior systemic treatment is required. In endometrial cancer, it is approved for patients who have already received platinum-based chemotherapy. For kidney cancer, the regimen your oncologist recommends determines where lenvatinib fits in the treatment sequence. Ask your oncologist which line of treatment applies to your situation, so you understand whether this is being offered as a first choice or because an earlier treatment has not held.
Did you know?
Lenvatinib is among very few targeted medicines approved across four distinct cancer types. Despite that breadth, the eligibility criteria within each cancer are specific — not every patient with that diagnosis qualifies.
In endometrial cancer, according to NCCN and ESMO guidelines, the MMR or MSI test result is not optional — it directly determines which treatment combination is appropriate for that patient.
Source: NCCN Clinical Practice Guidelines in Oncology; ESMO Clinical Practice Guidelines
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Can I take lenvatinib if my blood pressure is already high?
Yes, existing high blood pressure does not exclude you. Lenvatinib commonly causes blood pressure to rise further, so your team will measure and address it before you start. Blood pressure is checked regularly during treatment and your medicines may be adjusted. What matters is that it can be managed — not that it is already perfect. Tell your oncologist about any blood pressure medicines you currently take, including anything bought without a prescription.
How long does it take to find out whether I am eligible?
For thyroid and liver cancer, your oncologist can often determine eligibility from staging scans and biopsy reports you already have, without new tests. For kidney cancer, the histology report that identified the tumour type is usually sufficient. For endometrial cancer, the MMR or MSI test typically takes one to two weeks from when the laboratory receives the sample, and it is usually run on tissue from your existing biopsy. If all results are available, your oncologist may be able to discuss eligibility at your next scheduled appointment.
I have been prescribed lenvatinib. Should I get a second opinion first?
A second opinion is always reasonable before starting a new treatment, and your oncologist should not be offended. Ask for your biopsy and staging reports, your biomarker test results if applicable, and a clear summary of why lenvatinib was recommended. A second oncologist reviewing those same results will either confirm the recommendation — which is reassuring — or offer a different view that is worth considering. Either outcome helps you make an informed decision. CION oncologists can facilitate second opinion reviews.
Is lenvatinib treatment available at CION?
Yes. Lenvatinib is given as day care at CION centres — you do not need to stay overnight. Response-assessment imaging such as PET-CT is coordinated with partner imaging centres. If you have been told you may need CAR-T or cell therapy, that requires referral to a specialist centre, as CION does not provide cell therapies. Ask your CION oncologist which centre near you manages lenvatinib treatment for your cancer type.
What tests will be done before I can start lenvatinib?
Your team will typically check blood counts, kidney function, liver function, thyroid function, and urine protein levels before starting. Blood pressure is measured and treated if needed. Depending on your other health conditions, an ECG to check heart rhythm may also be requested. The exact set of tests depends on your cancer type and general health. These baseline checks are not obstacles — they make it safe to monitor you accurately once treatment begins and to spot any changes early.
What happens if I am found not to be eligible for lenvatinib?
Being ineligible does not mean you have run out of options. For each cancer type where lenvatinib is used, there are alternative approved treatments. Your oncologist will explain which one applies to your stage and history, and what it is intended to achieve. Ask them to explain, in plain terms, why lenvatinib was ruled out and what the alternative is. A clear answer to both is reasonable to expect, and you are entitled to ask for it in writing if that helps your family understand the plan.